Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially ava...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2019/5085373 |